d3bio.org Logo
  • About D3Bio
    • D3Bio’s Commitment
    • D3Bio Advisory Board
    • D3Bio Supporters
    • OTEF
    • OTEF Leadership
    • Privacy Policy
  • D3Bio News
    • AZ Pipeline
  • Programs
    • Internship Opportunities
  • Resources
    • AZBio.TV
    • Arizona BioMap
    • Arizona Bioindustry Fact Sheet
  • Contact D3Bio
  • Donate
  • Menu

HTG receives US patent for HTG EdgeSeq chemistry

Posted on June 17, 2014January 13, 2018 by D3Bio

HTG Receives US Patent for HTG EdgeSeq Chemistry Coupling Quantitative Nuclease Protection With Next-Generation-SequencingContinue reading→

Senestech signs exclusive licensing agreement with Neogen

Posted on June 16, 2014January 13, 2018 by D3Bio

AZBio Member Senestech has entered into an exclusive licensing agreement with Neogen to manufacture and market a rodent control product that uses fertility control to manage rat populations.Continue reading→

Slepian-Led Startup Targets Paradigm Shift in Heart Valve Surgery

Posted on June 12, 2014January 13, 2018 by D3Bio

University Relations – Communications | June 11, 2014Dr. Marvin J. Slepian, UA professor of medicine and biomedical engineering and a cardiologist at the UA Sarver Heart Center, is the founding CEO of PolyNova.Continue reading→

TGen and Arizona Community Foundation partner to support ASU football concussion research

Posted on June 10, 2014January 13, 2018 by D3Bio

TGen Concussion Research Fund is first under ACF’s new Jerry Colangelo Center for Sports PhilanthropyContinue reading→

HTG Launches an Automated, Sequencing-Based miRNA Whole Transcriptome Digital Gene Expression Assay for Challenging Sample Types

Posted on June 10, 2014January 13, 2018 by D3Bio

TUCSON, AZ– – Today HTG Molecular Diagnostics announced the availability of HTG EdgeSeq miRNA Whole Transcriptome Assay for measuring the expression of 2,275 human microRNAs (miRNAs) described in the miRBase v20 database.Continue reading→

New therapy for pancreatic cancer patients shows promising results

Posted on June 5, 2014January 13, 2018 by D3Bio

TGen-Scottsdale Healthcare lead international clinical trials in advance of FDA application for NAPOLI-1Continue reading→

ASU receives Gates grant for research in global health

Posted on June 5, 2014January 13, 2018 by D3Bio

Arizona State University has been awarded a Grand Challenges Explorations grant, an initiative funded by the Bill & Melinda Gates Foundation. Biodesign Institute researcher Shengxi Chen will pursue a global health and innovation project to design a better, next-generation condom.Continue reading→

Insys Therapeutics Cannabiodol Receives Orphan Drug Status for Lennox-Gastaut syndrome

Posted on June 4, 2014January 13, 2018 by D3Bio

On June 2, 2014 the FDA designated Insys Therapeutics’ (INSY) cannabidiol an Orphan Drug for the treatment of Lennox-Gastaut syndrome. (See FDA Site) The firm submitted its Type II Drug Master File to the FDA on May29.   A copy of the Insys release on the filing is provided below.

 

Continue reading→

ASU embarks on $9 million next phase of an effort to assess rapidly an absorbed radiation dose

Posted on June 3, 2014January 13, 2018 by D3Bio

Arizona State University’s Biodesign Institute announced today it is entering a new, $9 million phase of a multi-million, multi-institutional development project to produce a diagnostic test to measure rapidly an individual’s level of absorption of ionizing radiation in the event of an unplanned radiological or nuclear event. Continue reading→

BioPharm Insight: Regenesis now sees exit as sale to strategic player in 12 to 24 months – CEO

Posted on April 11, 2014January 13, 2018 by D3Bio

Regenesis Biomedical, a Scottsdale, Arizona-based medical device company, now sees a sale to a strategic in 2015 or 2016 as its likely exit, said CEO Scott Brooks.Continue reading→

Post navigation

« Previous 1 2 3 4 5 6 Next »

D3Bio Events

  • No events
  • all events
  • Disclaimer
    Privacy Policy
    Cookie Policy (EU)
    Cookie Policy (UK)
    Do Not Sell My Personal Information

    © Opportunity Through Entrepreneurship Foundation 2014 -2023
    Manage Cookie Consent
    We use cookies to optimize our website and our service.
    Functional cookies Always active
    The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
    Preferences
    The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
    Statistics
    The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
    Marketing
    The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
    Manage options Manage services Manage vendors Read more about these purposes
    View preferences
    {title} {title} {title}
    Manage Cookie Consent
    We use cookies to optimize our website and our service.
    Functional cookies Always active
    The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
    Preferences
    The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
    Statistics
    The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
    Marketing
    The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
    Manage options Manage services Manage vendors Read more about these purposes
    View preferences
    {title} {title} {title}